Indian pharmaceutical firms are seen re-calibrating their strategy for the US market in an increasingly competitive environment aggravated by price erosion and the growing cost of compliance.
While it’s not as if some sharp exodus is in the offing, but there’s a shift away, at least at...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
